H.B. Fuller plans to acquire Advanced Medical Solutions, expanding its medical adhesives portfolio, global reach, innovation capabilities, and long-term revenue growth.
H.B. Fuller Company, the world’s largest pure-play adhesives manufacturer, has announced a recommended cash offer to acquire Advanced Medical Solutions Group plc (AMS), a leading developer and manufacturer of advanced wound care and surgical products. The proposed acquisition represents a major milestone in H.B. Fuller’s long-term strategy to strengthen its presence in the global medical adhesives and healthcare solutions market. By integrating AMS’s innovative product portfolio, research capabilities, and global operations, H.B. Fuller aims to accelerate its transformation into a higher-growth, higher-margin business while expanding its footprint in one of the most attractive and resilient healthcare segments.
Celeste Mastin, President and Chief Executive Officer of H.B. Fuller, emphasized that the acquisition aligns perfectly with the company’s strategic vision. She noted that the healthcare and medical adhesives sector has consistently been identified as one of H.B. Fuller’s priority growth markets due to its stable demand, attractive profit margins, and stringent regulatory requirements that create significant barriers for new competitors. According to Mastin, the company has spent considerable time evaluating opportunities within this highly specialized market and believes AMS represents one of the strongest strategic assets available.
Advanced Medical Solutions has built a strong reputation as a leading innovator in surgical adhesives, wound closure technologies, tissue bonding solutions, and biosurgical products. Its innovation-driven business model, broad product portfolio, advanced research and development capabilities, and established global commercial network make it an ideal complement to H.B. Fuller’s existing healthcare operations. The acquisition is expected to generate meaningful revenue growth opportunities while delivering operational efficiencies through cost optimization and enhanced manufacturing capabilities.
One of the most significant benefits of the transaction is the expansion of H.B. Fuller’s total addressable market (TAM). By incorporating AMS’s portfolio of differentiated surgical adhesive technologies, formulated biosurgicals, tapes, dressings, and tissue bonding products, H.B. Fuller estimates that its addressable market will increase by approximately $15 billion, bringing its overall TAM to nearly $95 billion. This substantial expansion positions the company to capitalize on growing demand across the global healthcare industry.
The acquisition also significantly strengthens H.B. Fuller’s commercial reach. AMS has developed a dedicated pan-European sales organization with deep relationships across hospitals, healthcare systems, and specialty distributors throughout Europe. This network is expected to create immediate cross-selling opportunities for H.B. Fuller’s existing medical adhesive portfolio. At the same time, AMS is expected to benefit from H.B. Fuller’s extensive manufacturing infrastructure, sales presence, and customer relationships across the United States, allowing the combined business to accelerate AMS’s penetration into the North American healthcare market.
Research, development, manufacturing, and regulatory expertise will also receive a substantial boost through the combination. AMS employs more than 75 specialized R&D professionals who have consistently delivered successful product innovations and commercial launches. Combining these capabilities with H.B. Fuller’s established medical technology expertise is expected to strengthen product development pipelines and shorten commercialization timelines. Operationally, the merged company will benefit from integrating H.B. Fuller’s advanced medical manufacturing facilities in the United States and Italy with AMS’s production sites located across the United Kingdom, Germany, France, the Netherlands, Thailand, and India. Furthermore, AMS brings extensive knowledge of global medical device regulatory approval processes, enabling faster market access while reducing regulatory and execution risks associated with new product development.
Financially, H.B. Fuller expects the acquisition to create significant long-term value through both revenue and cost synergies. The company projects approximately $55 million (around £41 million) in annualized revenue and operational savings by 2031. These benefits are expected to come from eliminating duplicated public company expenses, optimizing overlapping business functions, improving procurement efficiency, and leveraging combined sourcing capabilities across global operations.
The transaction is also expected to accelerate H.B. Fuller’s financial performance by adding roughly $300 million in annual revenue while supporting the company’s long-term objective of achieving 5% annual constant-currency revenue growth and EBITDA margins exceeding 20%. The inclusion of AMS’s higher-value healthcare products is anticipated to improve the company’s overall product mix, resulting in stronger profitability and sustainable earnings growth over the long term.
To enhance financial transparency, H.B. Fuller plans to establish a dedicated global medical business unit for reporting purposes. This new segment is expected to contribute approximately 10% of the combined company’s total revenue and EBITDA immediately following the completion of the acquisition, providing investors with greater visibility into the company’s growing healthcare business.
The proposed acquisition also builds upon H.B. Fuller’s proven record of successful mergers and acquisitions. Since 2023, the company has completed and integrated 11 acquisitions across attractive growth markets, significantly enhancing shareholder value. By the end of 2025, these acquisitions collectively contributed to a 55% increase in EBITDA while improving EBITDA margins by more than 1,000 basis points. The company has also consistently demonstrated its ability to reduce leverage following major acquisitions, reinforcing confidence in its disciplined capital allocation strategy and long-term financial management.
Overall, the acquisition of Advanced Medical Solutions represents a transformative strategic investment that is expected to strengthen H.B. Fuller’s leadership in medical adhesives, broaden its global healthcare presence, enhance innovation capabilities, improve operational efficiencies, and create sustainable long-term value for customers, shareholders, and other stakeholders.
Impact on Products and Chemical Commodity Prices Tracked by ChemAnalyst
H.B. Fuller’s proposed acquisition of Advanced Medical Solutions (AMS) is expected to have a positive long-term impact on the medical adhesives and wound care products market rather than creating an immediate disruption in chemical commodity prices. The combined company will likely witness increased production of surgical adhesives, tissue bonding products, wound dressings, sealants, and formulated biosurgical products, driving higher demand for specialty raw materials such as acrylic polymers, polyurethane-based materials, silicone adhesives, cyanoacrylates, hydrocolloids, and medical-grade resins. However, since the acquisition is primarily a strategic portfolio expansion and not a large-scale capacity addition, its immediate influence on bulk chemical markets tracked by ChemAnalyst is expected to remain limited. Prices of upstream petrochemical feedstocks such as acrylic acid, polyurethane intermediates, and specialty polymers are likely to remain largely stable in the short term, supported by existing supply-demand fundamentals. Over the medium to long term, sustained growth in healthcare manufacturing could moderately strengthen demand for specialty adhesive chemicals, potentially lending slight upward support to prices of selected high-value medical-grade chemical commodities.
